GlaxoSmithKline K.K. (GSK Japan) and Daiichi Sankyo Co. announced March 2 that GSK Biologicals, GSK Japan and Daiichi Sankyo have agreed to enter into a strategic alliance in the vaccine business and will form a vaccine joint venture in Japan.
The joint venture will be named Japan Vaccine Co. GSK and Daiichi Sankyo will invest equally in the venture.
JV intends to contribute to improving access to vaccines in Japan and introduce new vaccines for which vaccination is recommended overseas.
It will also increase product line-up by bringing together the technologies and products of its parent companies.
- « Prev
- Next »